The structural function of ATR in development, oncogenesis and cancer therapy
ATR 在发育、肿瘤发生和癌症治疗中的结构功能
基本信息
- 批准号:9886205
- 负责人:
- 金额:$ 42.18万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-04-01 至 2022-03-31
- 项目状态:已结题
- 来源:
- 关键词:ATR geneAffectAgingAllelesAppearanceCHEK1 geneCell Cycle CheckpointCellsCessation of lifeChromosomesCombined Modality TherapyDNA DamageDNA Double Strand BreakDNA RepairDNA biosynthesisDNA replication forkDNA-dependent protein kinaseDefectDevelopmentDominant-Negative MutationEmbryoEmbryonic DevelopmentEnterobacteria phage P1 Cre recombinaseEstrogen receptor positiveEvolutionFemaleGenetic ModelsGenetic RecombinationGenomic InstabilityGenotoxic StressGrowthHematopoiesisHumanHypersensitivityImpairmentIn VitroInfertilityKnock-inLymphocyteMalignant NeoplasmsMediatingMeiosisMicrocephalyMitoticModelingMusMutagensMutationOncogenesOncogenicPathway interactionsPhosphorylationPhosphotransferasesProcessProliferatingProteinsRNA SplicingRadiationReplication OriginResectedRoleSeckel syndromeSex ChromosomesSpermatogenesisSterilityStructureStructure of thyroid parafollicular cellSymptomsTP53 geneTamoxifenTestingTherapeuticTherapeutic EffectTumor Suppressionbasecancer cellcancer initiationcancer therapychemotherapyexhaustgenotoxicityin vivoin vivo regenerationinhibitor/antagonistkinase inhibitorleukemiamalemouse modeloverexpressionpreclinical trialprematurepreventreplication stressresponseside effectstemstem cellstissue culturetissue regenerationtumorigenesis
项目摘要
PROJECT SUMMARY/ABSTRACT
Genomic instability drives cancer initiation, progression and treatment. The ATR kinase is a master regulator of
DNA damage responses (DDRs) during DNA replication and strand breaks. Although complete loss of ATR
(Atr-/-) abrogates embryonic development and cellular viability, ATR kinase inhibitors are well-tolerated in
preclinical trials and have generated promising therapeutic effects when used in combination with genotoxic
treatments including radiation. To determine whether ATR protein has a structural function in DNA replication
and repair (i.e., independent of its kinase activity or regulated by auto-phosphorylation), we generated a mouse
model expressing kinase-dead ATR protein (AtrKD). Atr+/KD mice are born at expected Mendelian ratio and of
normal size. Moreover somatic inactivation of the Atr conditional allele (AtrC) using Tamoxifen inducible Cre
recombinase is very well tolerated in AtrC/KD mice but not AtrC/- mice. While female Atr+/KD mice are fertile, Atr+/KD
male mice are sterile due to meiosis defects during spermatogenesis that were not seen in Atr+/- mice. Here we
propose to use the Atr null (Atr-), conditional (AtrC), and kinase-dead (AtrKD) mouse models to investigate
kinase-independent structural function during normal DNA replication and aging (aim 1), auto-phosphorylation
dependent dominant negative function of AtrKD protein during spermatogenesis(aim 2) and the oncogenic
potential as well as the chemo-sensitivity profile of the AtrKD mutation. Together, the results will elucidate the
structural functions of ATR during DNA repair and oncogenesis, and the mechanisms underlying the
therapeutic as well as side effects of ATR inhibition.
项目总结/摘要
基因组不稳定性驱动癌症的发生、进展和治疗。ATR激酶是一种主要的调节因子,
DNA复制和链断裂过程中的DNA损伤反应(DDRs)。虽然ATR完全丧失
(Atr-/-)消除胚胎发育和细胞活力,ATR激酶抑制剂在哺乳动物中耐受良好。
临床前试验,并产生了有希望的治疗效果时,与遗传毒性组合使用
治疗包括放射治疗。为了确定ATR蛋白在DNA复制中是否具有结构功能,
并修复(即,独立于其激酶活性或受自身磷酸化调节),我们产生了小鼠
表达激酶死亡ATR蛋白(AtrKD)的模型。Atr+/KD小鼠以预期的孟德尔比率出生,
正常大小。此外,使用他莫昔芬诱导的Cre对Atr条件等位基因(AtrC)进行体细胞失活,
重组酶在AtrC/KD小鼠中耐受性非常好,但在AtrC/-小鼠中不是。虽然雌性Atr+/KD小鼠是可生育的,但Atr+/KD
雄性小鼠由于在精子发生期间的减数分裂缺陷而不育,这在Atr+/-小鼠中未观察到。这里我们
我建议使用Atr null(Atr-)、条件性(AtrC)和激酶死亡(AtrKD)小鼠模型来研究
正常DNA复制和老化过程中激酶非依赖性结构功能(目的1),自磷酸化
AtrKD蛋白在精子发生过程中的依赖性显性负功能(aim 2)和致癌性
潜在的以及AtrKD突变的化学敏感性概况。总之,这些结果将阐明
ATR在DNA修复和肿瘤发生过程中的结构功能,以及其潜在的机制,
治疗以及ATR抑制的副作用。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Shan Zha其他文献
Shan Zha的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Shan Zha', 18)}}的其他基金
The role of DNA-PKcs in DNA repair, lymphocyte development, RNA metabolism and tumor suppression
DNA-PKcs 在 DNA 修复、淋巴细胞发育、RNA 代谢和肿瘤抑制中的作用
- 批准号:
10539944 - 财政年份:2022
- 资助金额:
$ 42.18万 - 项目类别:
The role of DNA-PKcs in DNA repair, lymphocyte development, RNA metabolism and tumor suppression
DNA-PKcs 在 DNA 修复、淋巴细胞发育、RNA 代谢和肿瘤抑制中的作用
- 批准号:
10651884 - 财政年份:2022
- 资助金额:
$ 42.18万 - 项目类别:
The non-catalytic function of PARP2 in DNA repair and cancer therapy
PARP2在DNA修复和癌症治疗中的非催化功能
- 批准号:
10641934 - 财政年份:2022
- 资助金额:
$ 42.18万 - 项目类别:
The non-catalytic function of PARP2 in DNA repair and cancer therapy
PARP2在DNA修复和癌症治疗中的非催化功能
- 批准号:
10540084 - 财政年份:2022
- 资助金额:
$ 42.18万 - 项目类别:
The catalytic and non-catalytic functions of PARP1 in cancer biology
PARP1 在癌症生物学中的催化和非催化功能
- 批准号:
10377548 - 财政年份:2018
- 资助金额:
$ 42.18万 - 项目类别:
The catalytic and non-catalytic functions of PARP1 in cancer biology
PARP1 在癌症生物学中的催化和非催化功能
- 批准号:
9886208 - 财政年份:2018
- 资助金额:
$ 42.18万 - 项目类别:
DNA-PKCS Phosphorylation in DNA Repair and Chromosomal Translocations
DNA 修复和染色体易位中的 DNA-PKCS 磷酸化
- 批准号:
8975763 - 财政年份:2014
- 资助金额:
$ 42.18万 - 项目类别:
相似海外基金
Hormone therapy, age of menopause, previous parity, and APOE genotype affect cognition in aging humans.
激素治疗、绝经年龄、既往产次和 APOE 基因型会影响老年人的认知。
- 批准号:
495182 - 财政年份:2023
- 资助金额:
$ 42.18万 - 项目类别:
Parkinson's disease and aging affect neural activation during continuous gait alterations to the split-belt treadmill: An [18F] FDG PET Study.
帕金森病和衰老会影响分体带跑步机连续步态改变期间的神经激活:[18F] FDG PET 研究。
- 批准号:
400097 - 财政年份:2019
- 资助金额:
$ 42.18万 - 项目类别:
The elucidation of the mechanism by which intestinal epithelial cells affect impaired glucose tolerance during aging
阐明衰老过程中肠上皮细胞影响糖耐量受损的机制
- 批准号:
19K09017 - 财政年份:2019
- 资助金额:
$ 42.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Does aging of osteocytes adversely affect bone metabolism?
骨细胞老化会对骨代谢产生不利影响吗?
- 批准号:
18K09531 - 财政年份:2018
- 资助金额:
$ 42.18万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
Links between affect, executive function, and prefrontal structure in aging: A longitudinal analysis
衰老过程中情感、执行功能和前额叶结构之间的联系:纵向分析
- 批准号:
9766994 - 财政年份:2018
- 资助金额:
$ 42.18万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9320090 - 财政年份:2017
- 资助金额:
$ 42.18万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
10166936 - 财政年份:2017
- 资助金额:
$ 42.18万 - 项目类别:
Affect regulation and Beta Amyloid: Maturational Factors in Aging and Age-Related Pathology
影响调节和 β 淀粉样蛋白:衰老和年龄相关病理学中的成熟因素
- 批准号:
9761593 - 财政年份:2017
- 资助金额:
$ 42.18万 - 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
- 批准号:
9925164 - 财政年份:2016
- 资助金额:
$ 42.18万 - 项目类别:
Experimental Model of Depression in Aging: Insomnia, Inflammation, and Affect Mechanisms
衰老过程中抑郁症的实验模型:失眠、炎症和影响机制
- 批准号:
9345997 - 财政年份:2016
- 资助金额:
$ 42.18万 - 项目类别:














{{item.name}}会员




